Bioeq’s Lucentis Biosimilar Is Given EU Go-Ahead
Launch Dates And Financial Terms Of A Marketing Deal With Teva Remain Under Wraps
Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.
You may also be interested in...
As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.
In the wake of a positive opinion from the EMA’s CHMP recommending granting a marketing authorization for the firm’s Sandoz-partnered natalizumab biosimilar, Polpharma Biologics CEO Michael Soldan talks to Generics Bulletin about the significance of the development.
April brings news of further biosimilar competition to Lucentis in major European markets.